Posted by Michael Wonder on 02 May 2023
Erasca granted FDA fast track designation for CNS penetrant EGFR inhibitor ERAS-801 in patients with glioblastoma
1 May 2023 - Erasca today announced the United States FDA has granted fast track designation to ERAS-801 for the treatment of adult patients with glioblastoma with epidermal growth factor receptor (EGFR) gene alterations.
ERAS-801 is an orally bioavailable, small molecule EGFR inhibitor that exhibited substantial central nervous system penetration in animal studies.
